CardioInsight appoints new chief
Non-invasive electrocardiographic mapping technology developer CardioInsight Technologies named Patrick Wethington its president & CEO, after previous chairman & CEO Steve Arless resigned suddenly in April.
Wethington was most recently president & CEO of HemoSphere, a medical device maker that was acquired by CryoLife, prior to which he worked at Guidant, Endocardial Solutions and CHF Solutions.
"Pat’s background in electrophysiology and his experience bringing novel products to the market will serve as important assets as CardioInsight continues to develop its ECVUE platform," chairman of the board Jim Bullock said in prepared remarks. "Pat has developed a track record of strong leadership throughout his career, and his addition is an important complement to the organization as we further validate ECVUE’s exciting potential of unique clinical applications."
OvaScience adds board director
Medical device company OvaScience added Thomas Malley to its board of directors.
Malley was board director of Cougar Biotechnology from 2007 to 2009, when Johnson & Johnson (NYSE:JNJ) bought the company. Malley has been president of Denver investment firm Mossrock Capital since 2007, prior to which, he worked at Janus Global Life Sciences Fund and was VP of the Janus healthcare team.
Fallon has worked as the chief physician executive and senior VP at Blue Cross Blue Shield of Massachusetts since 2004, prior to which he was CEO for Clinical Affairs at the State University of New York Downstate Medical Center and Partners Healthcare System.
Fallon is also a board advisor for the Temple University School of Medicine and chairman of the New England Health Institute.
One member joins EarlySense’s medical advisory board
Waltham, Mass.-based medical device maker EarlySense named David Bates to its medical advisory board.
Bates is senior VP for quality & safety and chief quality officer for Brigham & Women’s Hospital in Boston. He is also a professor of medicine at Harvard Medical School, and professor of health policy & management at the Harvard School of Public Health, where he co-directs the clinical effectiveness program.
Smith & Nephew’s non- executive director leaves
Global medical device maker Smith & Nephew’s (FTSE:SN, NYSE:SNN) non-executive director Geneviève Berger resigned from the position because of “wider time commitments.”
Berger has been the chief research & development officer of Unilever plc and Unilever NV since 2008, prior to which he worked at the French Ministry for Education, Research & Technology.